Trial Outcomes & Findings for Functional Electrical Stimulation for Footdrop in Hemiparesis (NCT NCT00148343)
NCT ID: NCT00148343
Last Updated: 2018-06-01
Results Overview
Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).
COMPLETED
NA
110 participants
Weeks 0, 12, 24, 36
2018-06-01
Participant Flow
Subjects screened over 5-yr study period: 469. Subjects completing informed consent and eligibility eval: 158. Subjects enrolled: 110. Last date of enrollment:10/27/2009. Final date subject study completion: 8/2/2010. All subject screening, enrollment, and study participation took place at an academic medical center.
Enrolled subjects (n=110) were stratified by presence or absence of dorsiflexion, based on clinical exam, prior to randomization into treatment and control groups. No enrolled subjects were excluded from the trial prior to assignment to groups.
Participant milestones
| Measure |
Peroneal Nerve Stimulation (PNS)
The peroneal nerve stimulator used in this study was the Odstock Dropped-Foot Stimulator (ODFS).
|
Standard of Care (no Device or Ankle Foot Orthosis)
Conventional Standard of Care was defined as either 1) no device or 2) a custom molded hinged ankle foot orthosis (AFO). Standard of care intervention device was determined based on clinical indication.
|
|---|---|---|
|
Overall Study
STARTED
|
54
|
56
|
|
Overall Study
COMPLETED
|
39
|
45
|
|
Overall Study
NOT COMPLETED
|
15
|
11
|
Reasons for withdrawal
| Measure |
Peroneal Nerve Stimulation (PNS)
The peroneal nerve stimulator used in this study was the Odstock Dropped-Foot Stimulator (ODFS).
|
Standard of Care (no Device or Ankle Foot Orthosis)
Conventional Standard of Care was defined as either 1) no device or 2) a custom molded hinged ankle foot orthosis (AFO). Standard of care intervention device was determined based on clinical indication.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
12
|
7
|
|
Overall Study
Physician Decision
|
3
|
4
|
Baseline Characteristics
Functional Electrical Stimulation for Footdrop in Hemiparesis
Baseline characteristics by cohort
| Measure |
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 Participants
No device or ankle foot orthosis
|
Total
n=110 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
47 Participants
n=99 Participants
|
51 Participants
n=107 Participants
|
98 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
7 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Age, Continuous
|
52.8 years
STANDARD_DEVIATION 12.2 • n=99 Participants
|
53.2 years
STANDARD_DEVIATION 10.1 • n=107 Participants
|
53.0 years
STANDARD_DEVIATION 11.1 • n=206 Participants
|
|
Sex: Female, Male
Female
|
24 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
43 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
30 Participants
n=99 Participants
|
37 Participants
n=107 Participants
|
67 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
54 participants
n=99 Participants
|
56 participants
n=107 Participants
|
110 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Weeks 0, 12, 24, 36Population: For intent-to-treat analysis, all participants who were randomized and completed baseline assessments were included in the analysis
Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).
Outcome measures
| Measure |
Peroneal Nerve Stimulation
n=53 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=55 Participants
No device or ankle foot orthosis
|
|---|---|---|
|
Fugl-Meyer Motor Assessment (FMA)
Baseline
|
20.1 units on a scale
Standard Deviation 5.9
|
20.3 units on a scale
Standard Deviation 6.0
|
|
Fugl-Meyer Motor Assessment (FMA)
12- weeks
|
21.5 units on a scale
Standard Deviation 6.27
|
21.18 units on a scale
Standard Deviation 5.72
|
|
Fugl-Meyer Motor Assessment (FMA)
24- weeks
|
21.26 units on a scale
Standard Deviation 6.05
|
21.17 units on a scale
Standard Deviation 5.58
|
|
Fugl-Meyer Motor Assessment (FMA)
36 weeks
|
21.93 units on a scale
Standard Deviation 5.84
|
21.02 units on a scale
Standard Deviation 5.69
|
SECONDARY outcome
Timeframe: Weeks 0, 12, 24, 36The number of steps taken by participants in one minute
Outcome measures
| Measure |
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 Participants
No device or ankle foot orthosis
|
|---|---|---|
|
Steps Per Minute
Baseline
|
65.0 Steps/Min
Standard Deviation 22
|
66.7 Steps/Min
Standard Deviation 22.7
|
|
Steps Per Minute
12-weeks
|
67.4 Steps/Min
Standard Deviation 21.5
|
72.6 Steps/Min
Standard Deviation 22.6
|
|
Steps Per Minute
24-weeks
|
69.3 Steps/Min
Standard Deviation 26.35
|
72.0 Steps/Min
Standard Deviation 23.16
|
|
Steps Per Minute
36-weeks
|
70.84 Steps/Min
Standard Deviation 26.83
|
73.74 Steps/Min
Standard Deviation 22.73
|
SECONDARY outcome
Timeframe: Weeks 0, 12, 24, 36The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the "timed up-and-go" test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.
Outcome measures
| Measure |
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 Participants
No device or ankle foot orthosis
|
|---|---|---|
|
Modified Emory Functional Ambulation Profile(mEFAP)
Baseline
|
121.54 seconds
Standard Deviation 86.59
|
118.39 seconds
Standard Deviation 74.10
|
|
Modified Emory Functional Ambulation Profile(mEFAP)
12- weeks
|
107.92 seconds
Standard Deviation 78.80
|
93.47 seconds
Standard Deviation 73.02
|
|
Modified Emory Functional Ambulation Profile(mEFAP)
24-weeks
|
110.81 seconds
Standard Deviation 81.89
|
97.25 seconds
Standard Deviation 71.4
|
|
Modified Emory Functional Ambulation Profile(mEFAP)
36-weeks
|
111.81 seconds
Standard Deviation 83.16
|
96.20 seconds
Standard Deviation 65.20
|
SECONDARY outcome
Timeframe: Weeks 0, 12, 24, 36The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales. Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.
Outcome measures
| Measure |
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 Participants
No device or ankle foot orthosis
|
|---|---|---|
|
Stroke-Specific Quality of Life Scale (SS-QOL)
Baseline
|
179.12 Summary Score
Standard Deviation 35.73
|
175.30 Summary Score
Standard Deviation 40.67
|
|
Stroke-Specific Quality of Life Scale (SS-QOL)
12-weeks
|
191.62 Summary Score
Standard Deviation 42.39
|
185.42 Summary Score
Standard Deviation 34.76
|
|
Stroke-Specific Quality of Life Scale (SS-QOL)
24-weeks
|
195.66 Summary Score
Standard Deviation 38.25
|
184.87 Summary Score
Standard Deviation 38.88
|
|
Stroke-Specific Quality of Life Scale (SS-QOL)
36-weeks
|
190.23 Summary Score
Standard Deviation 44.73
|
182.95 Summary Score
Standard Deviation 39.76
|
SECONDARY outcome
Timeframe: baseline, 12, 24 and 36 weeksOutcome measures
| Measure |
Peroneal Nerve Stimulation
n=54 Participants
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 Participants
No device or ankle foot orthosis
|
|---|---|---|
|
Gait Speed
Baseline
|
0.35 meters/sec
Standard Deviation 0.20
|
0.40 meters/sec
Standard Deviation 0.24
|
|
Gait Speed
12-weeks
|
0.40 meters/sec
Standard Deviation 0.25
|
0.47 meters/sec
Standard Deviation 0.24
|
|
Gait Speed
24-weeks
|
0.44 meters/sec
Standard Deviation 0.28
|
0.46 meters/sec
Standard Deviation 0.25
|
|
Gait Speed
36-weeks
|
0.44 meters/sec
Standard Deviation 0.28
|
0.47 meters/sec
Standard Deviation 0.24
|
Adverse Events
Peroneal Nerve Stimulation
Standard of Care
Serious adverse events
| Measure |
Peroneal Nerve Stimulation
n=54 participants at risk
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 participants at risk
No device or ankle foot orthosis
|
|---|---|---|
|
Infections and infestations
infection
|
0.00%
0/54
|
1.8%
1/56 • Number of events 1
|
|
Musculoskeletal and connective tissue disorders
Muskuloskeletal
|
5.6%
3/54 • Number of events 3
|
3.6%
2/56 • Number of events 2
|
|
Musculoskeletal and connective tissue disorders
Fall
|
13.0%
7/54 • Number of events 10
|
3.6%
2/56 • Number of events 2
|
|
Nervous system disorders
Neurologic change
|
13.0%
7/54 • Number of events 8
|
0.00%
0/56
|
|
Cardiac disorders
Cardiac
|
7.4%
4/54 • Number of events 4
|
5.4%
3/56 • Number of events 3
|
|
Gastrointestinal disorders
Gastrointestinal
|
1.9%
1/54 • Number of events 1
|
0.00%
0/56
|
|
Psychiatric disorders
Psychiatric
|
0.00%
0/54
|
1.8%
1/56 • Number of events 1
|
|
Renal and urinary disorders
Urologic
|
1.9%
1/54 • Number of events 1
|
0.00%
0/56
|
Other adverse events
| Measure |
Peroneal Nerve Stimulation
n=54 participants at risk
Odstock Dropped Foot Stimulator
|
Standard of Care
n=56 participants at risk
No device or ankle foot orthosis
|
|---|---|---|
|
Injury, poisoning and procedural complications
Fall
|
46.3%
25/54 • Number of events 38
|
26.8%
15/56 • Number of events 24
|
|
Endocrine disorders
Endocrine
|
1.9%
1/54 • Number of events 1
|
0.00%
0/56
|
|
Musculoskeletal and connective tissue disorders
Muskuloskeletal
|
24.1%
13/54 • Number of events 16
|
7.1%
4/56 • Number of events 4
|
|
Nervous system disorders
Neurologic
|
3.7%
2/54 • Number of events 3
|
5.4%
3/56 • Number of events 3
|
|
Skin and subcutaneous tissue disorders
Skin
|
31.5%
17/54 • Number of events 21
|
7.1%
4/56 • Number of events 9
|
Additional Information
Lynne Sheffler, MD
Case Western Reserve University/MetroHealth Medcial Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place